A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
Condition:   Ebola Interventions:   Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo Sponsor:   Janssen Vaccines & Prevention B.V. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 14, 2020 Category: Research Source Type: clinical trials

Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola
Condition:   Ebola Virus Disease Intervention:   Biological: Ad26.ZEBOV vaccine Sponsors:   Universiteit Antwerpen;   Johnson & Johnson;   Ace Africa;   Innovative Medicines Initiative;   Coalition for epidemic prepardness innovations;   University of Kinshasa Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2019 Category: Research Source Type: clinical trials

Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC
Condition:   Ebola Virus Disease Intervention:   Biological: Ad26.ZEBOV, MVA-BN-Filo vaccine Sponsors:   London School of Hygiene and Tropical Medicine;   Epicentre;   Ministère de la Santé de la RDC;   Médecins Sans Frontières, France;   Coalition for Epidemic Preparedness Innovations;   Janssen Vaccines & Prevention B.V.;   Public Health England Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 5, 2019 Category: Research Source Type: clinical trials

FDA Accepts Merck ’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus
KENILWORTH, N.J.--(BUSINESS WIRE)-- September 17, 2019 -- Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 17, 2019 Category: Pharmaceuticals Source Type: clinical trials

GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute
London/Washington, D.C. 06 August 2019 -- GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 7, 2019 Category: Pharmaceuticals Source Type: clinical trials

Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
Condition:   Ebola Virus Intervention:   Biological: cAd3-EBO S vaccine Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   US Military HIV Research Program Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials